CURX Stock News & Catalysts

FEATURED

Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission

Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition

Summary

May 14, 2026, 8:53 AM ·Globe Newswire

RECENT

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)

NEW YORK, May 12, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc. (NASDAQ:CURX) (the

May 12, 2026, 6:08 PM ·PRNewswire

CURX Investors Have Opportunity to Join Curanex Pharmaceuticals Inc Fraud Investigation with the Schall Law Firm

LOS ANGELES, April 30, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Curanex Pharmaceuticals Inc

Apr 30, 2026, 8:35 PM ·Globe Newswire

Rosen Law Firm Encourages Curanex Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – CURX

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc. (NASDAQ:CURX) resulting from allegations that

Apr 16, 2026, 10:55 AM ·Business Wire

Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease According to patient accounts, multiple critically ill patients

Apr 8, 2026, 7:47 AM ·Globe Newswire

Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care

Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology's most serious and underserved supportive-care markets Jericho, New York, April

Apr 6, 2026, 9:17 AM ·Globe Newswire

Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company's Evolution Into a Broader Therapeutics Development Company

Company expands strategic focus into one of oncology's most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (NASDAQ:CURX) ("Curanex" or the

Apr 2, 2026, 8:07 AM ·Globe Newswire

Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission

Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York, March 30, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals,

Mar 30, 2026, 5:35 PM ·Globe Newswire

Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission

Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement to GLP Toxicology Program Jericho, New York, March 18, 2026 (GLOBE

Mar 18, 2026, 8:00 AM ·Globe Newswire

Curanex Expands Scientific Advisory Board With Two Distinguished Researchers

New Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission and Intellectual Property Strategy Jericho, New York, March 12, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals

Mar 12, 2026, 9:30 AM ·Globe Newswire

Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board

New Advisors Bring 50+ Years of Leadership Experience With 2 of the Top 10 Global Pharmaceuticals Companies Jericho, New York, March 11, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (NASDAQ:CURX) ("Curanex"

Mar 11, 2026, 8:00 AM ·Globe Newswire

Curanex Forms World Class Scientific Advisory Board

Board Includes Former Fortune 100 Pharma Executive and Leading US Medical Research Academic Jericho, New York, March 05, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (NASDAQ:CURX) ("Curanex" or the

Mar 5, 2026, 8:00 AM ·Globe Newswire

Curanex Provides Operational Update on Key Regulatory Milestones

Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (NASDAQ:CURX) ("Curanex" or the "Company"),

Feb 25, 2026, 8:00 AM ·Globe Newswire

Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement

Jericho, New York, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a developmental-stage pharmaceutical company focused on discovering and developing botanical

Oct 22, 2025, 7:00 AM ·Globe Newswire

Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters

Jericho, New York, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (NASDAQ:CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and developing

Sep 12, 2025, 2:46 PM ·Globe Newswire

Curanex Pharmaceuticals Inc Common Stock CURX · News